A phase <scp>II</scp> study of alternating sunitinib and temsirolimus therapy in patients with metastatic renal cell carcinoma

Dylan B. Ness, Darcy B. Pooler, Steven Ades, Brian J. Highhouse, Bridget M. Labrie, Jie Zhou, Jiang Gui, Lionel D. Lewis, Marc S. ErnstoffCancer 2023 · DOI

TL;DR

This study investigated an alternating regimen of sunitinib and temsirolimus for metastatic renal cell carcinoma (mRCC), aiming to improve efficacy and reduce toxicity compared to monotherapy. Unfortunately, the regimen did not improve progression-free survival (PFS) and was therefore not recommended for further investigation.

What Problem Does This Paper Address?

Metastatic renal cell carcinoma (mRCC) is a significant health challenge, and while targeted therapies like sunitinib (a tyrosine kinase inhibitor, TKI) and temsirolimus (an mTOR inhibitor) have shown promise as single agents, there's a constant drive to improve treatment outcomes. The problem this paper addresses is the search for more effective and tolerable combination therapies for mRCC. The rationale for alternating sunitinib and temsirolimus stems from their distinct mechanisms of action (VEGF and mTOR pathways, respectively) and non-overlapping toxicities, suggesting a potential synergistic effect or reduced cumulative toxicity when given sequentially rather than concurrently. Previous attempts at combining these drugs concurrently were poorly tolerated, leading to the exploration of an alternating schedule.

Methods

This was a single-arm, open-label, phase II clinical trial conducted across two centers. Patients with mRCC received an alternating dosing schedule: 4 weeks of sunitinib (50 mg daily) followed by a 2-week rest, then 4 weeks of temsirolimus (25 mg weekly) followed by a 2-week rest. This 12-week cycle was repeated until unacceptable toxicity, disease progression, or withdrawal of consent. The primary endpoint was progression-free survival (PFS), with secondary endpoints including clinical response rate and toxicity profile. Patient data was analyzed using Kaplan-Meier methods for PFS.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Rationale for Alternating Regimens: The study highlights the scientific rationale behind alternating targeted therapies with different mechanisms of action to potentially overcome resistance and improve efficacy, while also aiming to mitigate the toxicity seen with concurrent administration.
  • Limited Benefit of Alternating Sunitinib/Temsirolimus: Despite the theoretical advantages, this specific alternating regimen did not demonstrate a significant improvement in PFS compared to historical data for monotherapy or other combinations.
  • Impact of Evolving Treatment Landscape: The study's early termination due to slow accrual underscores the rapid evolution of mRCC treatment, with the emergence of new therapies (like immune checkpoint inhibitors) significantly impacting clinical trial enrollment and standard of care.
  • Potential for Exceptional Responders: The observation of a few patients with remarkably long PFS (e.g., 36.9 and 59.4 months) suggests that further investigation into the mechanisms behind exceptional responses might be valuable.

Key Results

  • Patient Enrollment: 19 patients were enrolled, but the study was stopped early after 13 evaluable patients due to slow accrual and lack of a clear benefit signal.
  • Median PFS: The median observed PFS for the 13 evaluable patients was 8.8 months (95% CI 6.8–25.2 months).
  • Best Responses: Among 17 evaluable patients for response, there were 5 partial responses (26.3%), 9 stable disease (47.4%), and 3 disease progressions (15.8%).
  • Toxicity: Common toxicities included fatigue, decreased platelet count, increased creatinine, diarrhea, and oral mucositis. While generally manageable, some serious adverse events (SAEs) led to treatment discontinuation.
  • Study Termination: The study was terminated early due to slow accrual, influenced by the rapid advancement of mRCC therapies and an interim futility analysis.

Limitations and Future Work

  • Limitations:
    • Small Sample Size: The study closed prematurely, resulting in a small number of enrolled and evaluable patients, limiting statistical power.
  • Single-Arm Design: The lack of a control arm makes it difficult to definitively attribute outcomes solely to the alternating regimen.
  • Lack of Racial Diversity: The study population reflected the rural areas from which patients were recruited, limiting generalizability.
  • Future Work:
    • The authors conclude that this specific alternating regimen of sunitinib and temsirolimus is not recommended for further study due to the lack of demonstrated benefit and the changing standard of care.
  • They suggest that further investigation into the mechanisms of exceptional responders could be valuable for understanding therapeutic heterogeneity.

Summary updated

Abstract

Alternating sunitinib and temsirolimus did not improve the PFS in patients with mRCC.
BibTeX
@inproceedings{ness2023phase,
  author = {Dylan B. Ness and Darcy B. Pooler and Steven Ades and Brian J. Highhouse and Bridget M. Labrie and Jie Zhou and Jiang Gui and Lionel D. Lewis and Marc S. Ernstoff},
  title = {{A phase <scp>II</scp> study of alternating sunitinib and temsirolimus therapy in patients with metastatic renal cell carcinoma}},
  booktitle = {Cancer},
  year = {2023},
  doi = {10.1002/cam4.5990},
}
Figure